Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysisCapsule Summary

Background: Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system. Objective: To conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinum...

Full description

Bibliographic Details
Main Authors: Helen Y. Sun, BSc(Med)Hons, Elena Keller, MHEcon, Harish Suresh, BAct(Co-op), Deshan F. Sebaratnam, FACD
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:JAAD International
Subjects:
adalimumab
Australia
biologic therapy
cost-effectiveness analysis
cost-utility analysis
cost-benefit analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666328721000456

Internet

http://www.sciencedirect.com/science/article/pii/S2666328721000456

Similar Items